References
- Tikhomirov EM. Santamaria and K. Esteves, Meningococcal disease: public health butrlen and control. World Health Stat. Q. 50(3–4), 170–177 (1997).
- Gold R et al Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. j Infect. Dis.137(2), 112–121 (1978).
- Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. Exp. Merl 129 (6), 1327–1348 (1969).
- Sim RJ et al Underestimation of meningococci in tonsillar tissue bynasopharyngeal swabbing. Lancet 356(9242), 1653–1654 (2000).
- Mitchell MS, Rhoden, DL King EO. Lactose fermenting organisms resembling Akssetia meningitidis. Bacterial 90,560 (1965).
- Riordan T et al Acquisition and carriage of meningococci in marine commando recruits. Epidemiol Infect. 121(3), 495–505 (1998).
- Neal KR et al Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study. BE Merl J320(7238), 846–849 (2000).
- Rake G. Studies on meningococcus infection VI. The carrier problem. I Exp. Merl 59, 553–576 (1934).
- Ala!Aldeen DA et al. Dynamics of meningococcal long-term carriage among university students and their implications for mass vaccination. j Clin. Microbial. 38(6), 2311–2316 (2000).
- Blakebrough IS et al The epidemiology of infections due to Neisseria meningitidis and Neisseria lactamica in a northern Nigerian comrnunity.j Infect. Dis. 146(5), 626–637 (1982).
- De Wals P et al Longitudinal study of asymptomatic meningococcal carriage in two Belgian populations of schoolchildren. Infect. 6(2), 147–156 (1983).
- Connolly M, Noah N. Is group C meningococcal disease increasing inEurope? A report of surveillance of meningococcal infection in Europe 1993–6. European Meningitis Surveillance Group. Epidemiol Infect. 122(1), 41–49 (1999).
- Rosenstein NE et al The changing epidemiology of meningococcal disease inthe United States, 1992–1996.1 Infect. Dis. 180(6), 1894–1901 (1999).
- Pollard AJ, National Committee on Immunization (NACI). Statement on recommended use of meningococcal vaccines. Can. Comm. Dis. Rev 27(ACS6), 2–36 (2001).
- Lapeyssonnie L. La meningite cerebrospinale en Afrique. Bull. WHO 28\(Supp1.1), 3–114 (1963).
- Gray SJ et al Ultrasound-enhanced latex immunowlutination and PCR as complementary methods for nonculture-based confirmation of meningococcal disease. Clin. Mavbiol 37(6), 1797–1801 (1999).
- Borrow R et al. Nonculture diagnosis and serogroup determination of meningococcal B and C infection by a sialyltransferase (siaD) PCR ELISA. Epidemiol Infect. 118(2), 111–117 (1997).
- Kaczmarski EB et al. Creating a national service for the diagnosis of meningococcal disease by polymerase chain reaction. Commun. Dis. Public Ikalth1(1), 54–56 (1998).
- Booy R et al. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Arch. Dis. Child. 85(5), 386–390 (2001).
- Nadel S et al Avoidable deficiencies in the delivery of healthcare to children with meningococcal disease. J. Accid Emerg. Med. 15,298–303 (1998).
- Pollard AJ et al Emergency management of meningococcal disease. Arch. Dis. Child. 80(3), 290–296 (1999).
- Gheesling LL et al Multicenter comparison of Neisseria meningitidisserogroup C anti capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J. Clin. Microbial. 32(6), 1475–1482 (1994).
- Peltola H. Meningococcal vaccines. Current status and future possibilities. DITIF 55(3), 347–366 (1998).
- Granoff DM et al A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin. Diagn. Lab. hnmunol. 5 (4), 479–485 (1998).
- Maslanka SE et al Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin. Diagn. Lab. Imucunol. 4(2), 156–167 (1997).
- World Health Organisation, Requirements for meningococcal polysaccharide vaccine. World Health Organisation technical report series. Vol. 594. Geneva: World Health Organisation (1956).
- Borrow R et al Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: re-evaluation of correlates of protection. Infect. Immun. 69(3), 1568–1573 (2001).
- Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. Exp. Med129(6), 1307–1326 (1969).
- Zollinger WD, Mandrell RE. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect. Immun. 40(1), 257–264 (1983).
- Milagres LG et al Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect. Immun. 62(10), 4419–4424 (1994).
- Lehmann AK, Halstensen A, Rassoe CE Flow cytometric quantitation of human opsonin-dependent phagocytosis and oxidative burst responses to meningococcal antigens. Cytometry33(4), 406–413 (1998).
- Lehmann AK et al Human opsonins induced during meningococcal disease recognize transferrin binding protein complexes. Infect. Immun. 67(12), 6526–6532 (1999).
- Ross SC et al Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. J. Infect. Dis. 155(6), 1266–1275 (1987).
- Ison CA et al Assessment of immune response to meningococcal disease: comparison of a whole-blood assay and the serum bactericidal assay. Mcrob. Pathog. 27(4), 207–214 (1999).
- Finne J et al An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J. Immuno1.138 (12), 4402–4407 (1987).
- Swartley JS et al Capsule switching of Neisseria meningitidis. Proc. Natl Acad. Sci. USA 94(1), 271–276 (1997).
- Maiden MC, Spratt BG. Meningococcal conjugate vaccines: new opportunities and new challenges. Lancet 354(9179), 615–616 (1999).
- De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 285(2), 177–181 (2001).
- De Wals P et al Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada. Bull. World. Health. Chgan. 74(4), 407–411 (1996).
- Salleras L, Dominguez A, Prats G. Control of serogroup C meningococcal meningitis by mass vaccination in Catalonia (Spain). Vaccine 17\(Suppl. 3), S56-60 (1999).
- Biselli R et al. Dramatic reduction of meningococcal meningitis among military recruits in Italy after introduction of specific vaccination. Vacci7ell(5), 578–581 (1993).
- Rosenstein N et al Efficacy of meningococcal vaccine and barriers to vaccination. JAMA 279(6), 435–439 (1998).
- Artenstein MS, Brandt BL. Immunologic hyporesponsiveness in man to group C meningococcal polysaccharide. J. Immunol 115(1), 5–7 (1975).
- MacLennan J et al Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine17(23–24), 3086–3093 (1999).
- Peltola H et al Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl. J. Med. 297(13), 686–691 (1977).
- Law BJ et al Age-related immunogenicity of meningococcal polysaccharide vaccine in aboriginal children and adolescents living in a Northern Manitoba reserve community. Pecliatr Infect. Dis. J. 17(10), 860–864 (1998).
- Booy R et al Efficacy of Haemophilus intluenzae type b conjugate vaccine PRP-T Lancet 344(8919), 362–366 (1994).
- MacLennan J et al Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J. Infect. Dis. 183(1), 97–104 (2001).
- MacLennan JM et al Safety, immunogenicity and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants: A randomized controlled trial [see comments]. JA/V/A 283(21), 2795–801 (2000).
- Cartwright K, Noah N, Peltola H. Meningococcal disease in Europe: epidemiology, mortality and prevention with conjugate vaccines. Vaccine 19,4347–4356 (2001).
- Miller E, Salisbury D, Ramsay M. Planning, registration and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20\(Supp1.1), S58-67 (2001).
- Ramsay ME et aLEfficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 357 (9251), 195–196 (2001).
- Morley SL, Pollard AJ. Vaccine prevention of meningococcal disease, corning soon? Vaccine 20(5–6), 666–687 (2001).
- Fusco PC et al Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. J. Infect. Dis. 175(2), 364–372 (1997).
- Frasch CE. Meningococcal Vaccines: past present and future, in Meningococcal disease. Cartwright K, Ed. John Wiley and Sons, New York, NY, USA. 245–283 (1995).
- Zollinger WD et al Safety and immunogenicity of a Neisseria meningitidis Type 2 protein vaccine in animals and humans. J. Infect. Dis 137 (6), 728–739 (1978).
- Frasch CE et al Outer membrane protein vesicle vaccines for meningococcal disease, in Meningococcal Vaccines. Pollard AJ, Maiden MC (Eds.). Humana Press: Totowa, NJ, USA 81–107 (2001).
- Sierra GV et al Vaccine against group B Neisseria meningitidis protection trial and mass vaccination results in Cuba. NIPH Ann. 14(2), 195–207, discussion 208–210 (1991).
- de Moraes JC et al Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340(8827), 1074–1078 (1992).
- Noronha CP, Struchiner CJ, Halloran ME. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study Int. J. Epidemial 24(5), 1050–1057 (1995).
- Bjune G et al Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338(8775), 1093–1096 (1991).
- Tappero JVV et al Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAIVIA 281(16), 1520–1527 (1999).
- Perkins BA et al Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J. Infect. Dis 177(3), 683–691 (1998).
- Van Der Ley P, Poolman JT. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein. Infect. Immun. 60 (8), 3156–3161 (1992).
- Claassen I et al Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14(10), 1001–1008 (1996).
- Cartwright K et al Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 17(20–21), 2612–2619 (1999).
- de Kleijn ED et al Immunogenicity and safety of a hexavalent meningococcal outer-membrane- vesicle vaccine in children of 2–3 and 7–8 years of age. Vaccine 18(15), 1456–1466 (2000).
- Martin D et al Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J. Exp. Med. 185(7), 1173–1183 (1997).
- Moe GR, Tan S, Granoff DM. Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect. Immun. 67(11), 5664–5675 (1999).
- Lissolo L et al Evaluation of transferrin- binding protein 2 within the transferrin-binding protein complex as a potential antigen for future meningococcal vaccines. Infect. Immun. 63(3), 884–890 (1995).
- Abdel-Hadi H et al Investigation of the potential of App as a vaccine candidate. in Twelth International Neisseria conference. Galveston, HCC Inc. TX, USA (2000).
- Gomez JA, Criado MT, CM Ferreiros. Bactericidal activity of antibodies elicited against the Neisseria meningiticlis 37-kDa ferric binding protein (FbpA) with different adjuvants. FEMS Iminunal Med. Microbial. 20(1), 79–86 (1998).
- Carson SD et al Ferric enterobactin binding and utilization by Neisseria gonorrhoeae. J. Bacterial. 181(9), 2895–2901 (1999).
- Ala'Aldeen DA, HA Davies, SP Borriello. Vaccine potential of meningococcal FrpB: studies on surface exposure and functional attributes of common epitopes. Vaccine 12(6), 535–541 (1994).
- Johnson AS et al Analysis of the human Ig isotype response to lactoferrin binding protein A from Neisseria meningitidis. FEMS Immunal Med. Nlicrobial 25 (4), 349–354 (1995).
- Virji M et al Meningococcal Opa and Opc Proteins their role in colonization and invasion of human epithelial and endothelial cells. Mal Microbial 10(3), 499–510 (1993).
- Stephens DS, McGee ZA. Attachment of Neisseria meningiticlisto human mucosal surfaces: influence of pili and type of receptor cell. J. Infect. Dis. 143(4), 525–532 (1981).
- Rosenqvist E et al An ELISA study of the antibody response after vaccination with a combined meningococcal group B polysaccharide and serotype 2 outer membrane protein vaccine. MPH Ann. 6(2), 139–149 (1983).
- Munkley A et al Blocking of bactericidal killing of Neisseria meningitidis by antibodies directed against class 4 outer membrane protein. Mcrob. Pathog. 11(6), 447–452 (1991).
- Manning DS, Reschke DK, Judd RC. Omp85 proteins of Neisseria gonorrhoeae and Neisseria meningitidis are similar to Haemophilus influenzae D-15-Ag and Pasteurella multocida Oma87. Iamb. Pathog. 25(1), 11–21 (1998).
- Peak IR et al Identification and characterisation of a novel conserved outer membrane protein from Neisseria meningitidis. FEMS Immunal Med. Mcrobial 28(4), 329–334 (2000).
- Collins RF et al Analysis of the PilQ secretin from Neisseria meningitidisby transmission electron microscopy reveals a dodecameric quaternary structure. J. Bacterial. 183(13), 3825–3832 (2001).
- Davies RL, Wall RA, Borriello SR Comparison of methods for the analysis of outer membrane antigens of Neisseria meningitidis by western blotting. J. Immunal Meth. 134(2), 215–225 (1990).
- Lewis LA et al Molecular characterization of hpuAB, the haemoglobin—haptoglobin- utilization operon of Neisseria meningitidis. Mal Microbial. 23 (4), 737–749 (1997).
- Tettelin H et al Complete genome sequence of Neissetia meningitidisserogroup B strain MC58. Science 287(5459), 1809–1815 (2000).
- Parkhill J et al Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature 404(6777), 502–506 (2000).
- Poolman J, Berthet FX. Alternative vaccine strategies to prevent serogroup B meningococcal diseases. Vaccine 20( Suppl. 1), S24-26 (2001).
- Pizza M et al. Identification of vaccine candidates against serogroup B meningcccccus by whole-genome sequencing. Science 287(5459), 1816–1820 (2000).
- Giuliani MM et al Immunogenicity and bactericidal activity of conserved N meningitidisserogroup B antigens. in Twelfth International Pathogenic Neisseria Conference. Galveston: Healthcare Communications, Inc. TX, USA (2001).
- Brett PJ, Feavers I, Charalambous BM. Identification of peptides that mimic N. meningitidis LOS epitopes via the use of combinatorial phage-display libraries, in Meningococcal Vaccines, Pollard AJ, Maiden MC, Editors. Humana Press: Totowa, NJ, USA 181–197 (2001).
- Grothaus MC et al Selection of an immunogenic peptide mimic of the capsular polysaccharide of Neissetia meningitidisserogroup A using a peptide display library. Vaccine 18 (13), 1253–1263 (2000).
- Saukkonen K et al Comparative evaluation of potential components for group B meningococcal vaccine bypassive protection in the infant rat and in vitro bactericidal assay. Vaccine 7 (4), 325–328 (1989).
- Andersen SR et al Short-chain lipopolysaccharide mutants of serogroup B Neissetia meningitidis of potential value for production of outer membrane vesicle vaccines. Nlicrob. Pathog. 19(3), 159–168 (1995).
- Andersen SR. et al Outer membrane vesicle vaccines made from short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis: effect of the carbohydrate chain length on the immune response. Vaccine 15(11) 1225–1234 (1999).
- Plested JS et al Conservation and accessibility of an inner core lipopolysaccharide epitope of Neissetia meningitidis. Infect. Immun. 67(10) 5417–5426 (1999).
- Tang C, Moxon R, Levine MM. For discussion: live attenuated vaccines for group B meningococcus. Vaccine 17(2) 114–117 (1999).
- Oftung F et al Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine. Infect. Immun. 67(2), 921–927 (1999).
Websites
- Communicable disease surveillance centre, and the Meningococcal Reference Unit, Invasive Meningococcal Infections, England, and Wales, by age and serogroup. www.phls.co.uldfacts/Mening/ N%20Mening/meni-Quarters.htm, 2001.
- World Health Organisation, The Meningitis Vaccine Project. 2001. www.whointivaccines/intermediate/ meningococcus.htm.